Trulicity in the GLP-1 litigation
Trulicity is a once-weekly GLP-1 receptor agonist with a long history of use in diabetes care. Plaintiffs allege that the original warnings on Trulicity did not adequately describe the risk of gastroparesis, ileus, or chronic gallbladder injury.
Qualifying injuries
Documented Trulicity use plus hospitalization or formal diagnosis of a qualifying injury — gastroparesis, severe pancreatitis, intestinal obstruction, ileus, gallbladder disease, vision loss — supports a claim.